As of Nov 27
| +0.22 / +0.20%|
The 17 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 130.00, with a high estimate of 138.00 and a low estimate of 102.00. The median estimate represents a +20.37% increase from the last price of 108.00.
The current consensus among 20 polled investment analysts is to Buy stock in Gilead Sciences. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.